Technology that Innovates & Empowers
At Bioaltus Pharmaceuticals, we unleash the potential of technology and channelise it towards the betterment of healthcare. We believe in the power of innovation and its capability to cater to the modern healthcare challenges.
Regulatory Policy
All Drug Regulatory Affairs ( DRA ) like approval of New Drugs, Subsequent New Drugs, FDC`s, Test Licences, NOC`s, Import Registrations and Import Licences from CDSCO HQ are overseen by our efficient team. With a thorough coordination with the R&D team, it prepares the data for DCGI approval. It also ensures that all DCGI criteria are met.
Innovation & Technology
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry’s standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
It has survived not only five centuries, but also the leap into electronic typesetting, remaining essentially unchanged. It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.
Research & Development: Insights that Guide
Our R&D department is well invested in formulation development, analytical development and chemical research. We utilise our facilities to develop, optimise and standardise high grade formulations. Also, we conduct stability studies to ensure efficacy and potency, thereby acquiring a valid manufacturing licence of complex formulations that are-
Difficult to formulate
Need extended release profile
Need device pairing for higher potency
IPR
IPR, or the Immediate and Patterned Release Technology is proven to be more effective while requiring lesser dose administration over time. With IPR, 10% of the drug is released immediately, while the 90% drug is released discretely over a period of 10 hours.
As opposed to SR- Sustained Release, IPR is preferred, especially for diabetic patients as it helps them develop a tight glycemic control just as the drug is administered. At Bioaltus Pharmaceuticals, we endorse this technology, thereby enhancing the efficacy of our formulations.
